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This study was aimed at delineating molecular pathways
essential in gender-different pathogenesis of chronic kidney
diseases (CKD). Renal transcripts of nuclear receptors and
metabolic enzymes in male and female kidneys from 5/6
nephrectomized (Nx) rats 7 weeks post-Nx were examined
using branched DNA signal amplification assay. Nx-males had
marked kidney injury coupled with anemia and malnutrition.
Nx-females had moderate renal injury, and were free of
albuminuria, anemia, and malnutrition. Nx-males had
systemic and renal inflammation, which were largely absent
in Nx-females. Blood 17b-estradiol, testosterone, and
corticosterone did not change, whereas urinary testosterone
decreased in both genders. Compared to males, female
kidneys had higher androgen receptor (AR) and aryl
hydrocarbon receptor (AhR) but lower estrogen receptor a
(ERa). Compared to Nx-males, female remnant kidneys had
less decreases in ERa and peroxisome proliferator-activated
receptor a (PPARa), had no induction of AR and decrease of
acyl-CoA oxidase, whereas had induction of cytochrome P450
4a1 (Cyp4a1) but decrease of AhR. Renal protein expression
of a 52-kDa isoform of Wilm’s tumor 1 (WT1), transcription
factor critical in nephrogenesis, decreased dramatically in
Nx-males but largely preserved in Nx-females. In conclusion,
gender divergences in basal expression and alteration of ERa,
AR, AhR, WT1, and PPARa/Cyp4a1 during CKD may explain
gender differences in CKD progression and outcome of renal
transplantation.
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Chronic kidney disease (CKD) is a major social and
economic burden worldwide.1 Currently, there is no curative
pharmacological therapy; the most effective drugs for CKD,
angiotensin-converting enzyme inhibitors, decrease CKD
progression by less than 50%.2 Many studies have disclosed
various pathophysiological factors affecting CKD, such as sex
hormones, glucocorticoids, and inflammation. Nuclear
receptors are attractive therapeutic targets due to their
powerful physiological functions and accessibility by small
molecules. It is well known that the expression of a
given nuclear receptor is critical in determining its physio-
logical function. However, previous studies were mainly
focused on receptor ligands, with little known about
alterations in renal expression of these nuclear receptors
during CKD.
An intriguing reality of CKD is the gender disparity in the
progression of kidney diseases; men display a faster rate of
progression of certain CKD. Such a gender difference has
been verified in various animal models, which conclude
that androgens exaggerate kidney disease, whereas estrogens
confer renal protection.3–6 In women, the deterioration
of renal disease markedly accelerates after menopause,
further confirming the renal protective effects of
estrogens.3
The peroxisome proliferator-activated receptor a (PPARa)
is highly expressed in the liver and kidney. In the kidney,
PPARa and its target gene cytochrome P450 4a1 (Cyp4a1) are
primarily expressed in proximal tubules.7,8 PPARa is not only
essential in fatty acid metabolism, but important in anti-
inflammatory reactions.9–12 Acyl-CoA oxidase (AOX) and
Cyp4a1, two well-characterized PPARa-regulated genes, are
vital in the metabolism of fatty acids, important sources of
energy supply and signaling molecules. During acute renal
failure induced by ischemia/reperfusion, rat kidneys have
downregulation of PPARa, AOX, and Cyp4a1 mRNA,
whereas PPARa-null mice have exacerbated renal injury.13
Moreover, PPARa ligand WY-14643 protected wild-type, but
not PPARa-null mice, from cisplatin-induced acute renal
failure through inhibiting inflammatory response and
apoptosis.14 However, there was no report on alteration of
renal PPARa signaling during CKD.
The importance of aryl hydrocarbon receptor (AhR) in
normal renal function is clearly demonstrated by the
abnormity of kidney observed in AhR-null mice and mice
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treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin, the proto-
typical AhR ligand.15,16 AhR is constitutively activated by
unknown endogenous ligand(s).17 AhR activation has been
associated with a decrease in estrogen receptor a (ERa),18
disruption of Wilms’ tumor 1 (WT1) homeostasis, antago-
nism of hypoxia signaling pathway, and induction of
oxidative stress,19–22 all of which are important in renal
pathophysiology. Interestingly, protein expression of Cyp1a2,
the AhR target gene, is induced in both the liver and kidney
of male CKD rats,23 suggesting that AhR may be activated in
CKD males. However, there was no report on alteration of
renal AhR expression during CKD.
Aiming at identifying key molecular targets for novel
therapeutic modalities through combination therapy, this
study is an in vivo integrative study on the contribution
of certain nuclear receptors to gender-divergent CKD
progression. Without genetic defects or nephrotoxin
treatment, the 5/6-nephrectomized (Nx) rat is considered
the best animal model mimicking human CKD. A previous
study demonstrates that CKD progression is slower in
female Nx rats.24 In this study, branched DNA (bDNA)
signal amplification assay, a high-throughput and quanti-
tative technique for mRNA determination, was used to
examine gender-divergent renal mRNA expression of
ERa, androgen receptor (AR), glucocorticoid receptor
(GR), AhR, and PPARa, as well as AOX and Cyp4a1. These
genes were selected due to their aforementioned demon-
strated importance in renal function and their potential as
drug targets. Profound gender differences in renal basal
expression and alteration of these genes during CKD were
identified, and their associations with CKD severity were
examined.
RESULTS
Gender difference in the progression of CKD in Nx rats
Nx-male rats displayed significant kidney disease, indicated
by increased blood urea nitrogen, decreased creatinine
clearance (CrCl), proteinuria, and albuminuria (Table 1).
In contrast, Nx-females had much milder kidney injury: only
blood urea nitrogen was elevated and glomerular filtration
rate (GFR) was decreased; urinary protein and blood
creatinine tended to increase slightly. Males had higher basal
GFR than females; however, Nx-males only retained 34%,
whereas Nx-females maintained 60% of normal GFR. More-
over, Nx-males had an immune defect, anemia, and
malnutrition, manifested by splenomegaly, decreased blood
hemoglobin/hematocrit, and decreased blood albumin,
respectively; these pathological changes were absent in Nx-
females (Table 1).
Gender difference in renal activities of caspase-3
In Nx-males, renal caspase-3 activity increased 210%,
indicating increased apoptosis. In five of seven Nx-females,
caspase-3 activity remained similar to that in sham females,
but two of seven Nx-females displayed a striking elevation of
caspase-3 activity, resulting in a marked increase of mean
caspase-3 activity similar to that in Nx-males; however, such
an increase was statistically insignificant (Figure 1).
Gender difference in renal mRNA expression of
inflammation-related genes
Inflammation is essential in inducing apoptosis and renal
diseases. Nx-males had 76, 350, and 130% higher interleukin-
1beta (IL-1b), IL-6, and IL-10 transcripts than sham males,
respectively; whereas elevations of these cytokines were
Table 1 | Gender difference in CKD in 5/6 Nx rats
Sham male Nx-male Sham female Nx-female
Right kidney (mg/100 g body weight) 452721 479720 387711 422717
Spleen (mg/100 g body weight) 16078 23378a 21479 221710
Blood
Urea nitrogen (mg/dl) 22.172.3 73.3713.1a 17.571.2 33.672.9a,b
Creatinine (mg/dl) 0.7370.08 1.4270.20a 0.5670.06 0.7870.10b
Hemoglobin (g/dl) 14.670.36 11.970.72a 14.870.29 14.570.19b
Hematocrit (%) 45.071.3 35.872.1a 46.471.0 45.371.0b
Albumin (g/dl) 3.870.1 3.270.1a 4.470.04c 4.270.1b
Urine
24 h urine (ml) 26.274.1 39.773.8a 16.271.8 18.171.5b
Urea nitrogen (mg/24 h) 520738 374735a 305722c 290720
Albumin (mg/24 h) 7.170.82 12.171.4a 5.270.57 3.870.37b
Protein (mg/24 h) 10.471.2 61.5717.5a 6.471.3 12.673.6b
Systemic
Creatinine clearance (ml/min) 1.0270.11 0.4770.08a 0.8370.08 0.6470.13
Glomerular filtration rate (ml/min) 1.3670.08 0.4670.07a 1.0670.09c 0.6470.09a
CKD=chronic kidney disease; Nx=nephrectomized.
N=6–7. Mean7s.e.
aPo0.05 compared to corresponding sham control.
bPo0.05 compared to Nx-male rats.
cPo0.05 compared to sham male.
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largely absent in Nx-females (Figure 2a–c). In Nx rats, renal
transcripts of Fas, a key death receptor mediating inflamma-
tion-induced apoptosis, was elevated similarly in both
genders (Figure 2d); however, mRNA of FasL, the ligand
activating Fas, was only increased in Nx-males (Figure 2e).
Renal Fas mRNA correlated with proteinuria (r¼ 0.80) and
caspase-3 activity (r¼ 0.80) in Nx-males and Nx-females,
respectively. Thus, Nx-males had both systemic (spleno-
megaly) and renal inflammation, which is largely absent in
Nx-females.
Gender difference in blood and urine levels of steroid
hormones
In blood, sham females had higher corticosterone and 17b-
estradiol (E2) concentrations than sham males (Figure 3a and
b), whereas sham males had much higher testosterone
(Figure 3c). In Nx rats, corticosterone remained unchanged,
whereas testosterone and E2 tended to decrease (P40.05) in
males and females, respectively (Figure 3a–c). Testosterone
concentrations in urine wereB6-fold higher in sham females
than sham males, and decreased in both Nx-females and Nx-
males (Figure 3d). In Nx-males, urinary excretion of testo-
sterone correlated positively with GFR (r¼ 0.78). 17b-Estradiol
was not detectable in urine.
Gender difference in renal expression of steroid hormone
receptors
Sham females had 50% higher AR transcripts and slightly
(15%) higher GR transcripts than males (Figure 4a and b),
whereas sham males had 150% higher ERa transcripts than
sham females (Figure 4c). Renal GR transcripts was decreased
to a higher degree in Nx-females (40%) than Nx-males
(28%) (Figure 4a). Nx rats displayed marked gender
differences in renal sex hormone receptors: AR transcripts
increased by 40% in Nx-males but tended to decrease
(P¼ 0.06) in Nx-females (Figure 4b), whereas ERa tran-
scripts decreased 45% in Nx-males, but decreased slightly
(17%) in Nx-females (Figure 4c). Western blot data (Figure
4d) confirmed that basal protein expression of ERa was
higher in sham males than sham females, and ERa protein
expression decreased more dramatically in Nx-males than
Nx-females.
In Nx-males, renal GR transcripts correlated with GFR
(Figure 4e) and CrCl (r¼ 0.82), and ERa transcripts
correlated with multiple markers of kidney disease, such as
GFR (Figure 4f), CrCl (r¼ 0.83), and proteinuria
(r¼0.91). Renal AR did not correlate with any CKD
parameters.
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Figure 1 | Renal enzyme activities of caspase-3 in 5/6 Nx rats.
Kidney samples of male and female rats were collected 7 weeks after
Nx. Renal caspase-3 activity was determined with a diagnostic kit.
N¼ 6–7. Error bars indicate s.e.m. SM, sham-operated male rats;
NxM, 5/6 nephrectomized male rats; SF, sham-operated female rats;
NxF, 5/6 nephrectomized female rats. *Po0.05 compared to
corresponding sham-operated group.
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Figure 2 | Renal mRNA expression of inflammation-related genes
in 5/6 Nx rats. Kidney samples of male and female rats were
collected 7 weeks after Nx. The mRNA expression of (a) IL-1b), (b) IL-6,
(c) IL-10, (d) Fas, and (e) Fas ligand (FasL) in kidney total RNA was
quantified with the bDNA signal amplification assay. N¼ 6–7. Y axis
represents renal mRNA of target genes expressed as RLU per 4 mg
total RNA. Error bars indicate s.em. SM, sham-operated male rats;
NxM, 5/6 nephrectomized male rats; SF, sham-operated female
rats; NxF, 5/6 nephrectomized female rats. *Po0.05 compared to
corresponding sham-operated group; #Po0.05 compared to
corresponding male group.
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Gender difference in renal mRNA expression of PPARa and its
target genes
Renal PPARa mRNA decreased markedly in Nx-males
(44%), but moderately in Nx-females (24%), resulting
in a lower expression in Nx-males (Figure 5a). Renal AOX
decreased 42% in Nx-males, but was maintained in Nx-
females, resulting in lower expression in Nx-males (Figure 5b).
Importantly, in both Nx-males and Nx-females, renal PPARa
and AOX correlated with proteinuria (Figure 5c and d).
Renal basal expression of Cyp4a isoforms was gender
divergent: females had twofold higher Cyp4a1 (Figure 5e),
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Figure 3 | Blood and/or urine levels of E2, testosterone, and
corticosteroid in 5/6 Nx rats. Blood and urine samples of male and
female rats were collected 7 weeks after Nx. Blood and urine levels
of steroid hormones were determined with radioimmunoassay kits.
N¼ 6–7. Error bars indicate s.e.m. (a) Plasma levels of corticosterone,
(b) plasma levels of E2, (c) plasma levels of testosterone, and
(d) urinary excretion of testosterone. SM, sham-operated male rats;
NxM, 5/6 nephrectomized male rats; SF, sham-operated female rats;
NxF, 5/6 nephrectomized female rats. *Po0.05 compared to
corresponding sham-operated group; #Po0.05 compared to
corresponding male group.
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Figure 4 | Renal expression of steroid hormone receptors in 5/6
Nx rats. Kidney samples of male and female rats were collected
7 weeks after Nx. Renal mRNA expression of ERa, AR, and GR was
quantified with the bDNA signal amplification assay. Renal protein
expression of ERa was determined by Western blot. Y axis represents
renal mRNA of target genes expressed as RLU per 4 mg total RNA.
N¼ 6–7. Error bars indicate s.e.m. (a) GR mRNA, (b) AR mRNA, (c) ERa
mRNA, (d) ERa protein, (e) positive correlation of renal GR mRNA with
GFR in Nx-males, and (f) positive correlation of renal ERa mRNA
with GFR in Nx-males. SM, sham-operated male rats; NxM, 5/6
nephrectomized male rats; SF, sham-operated female rats; NxF, 5/6
nephrectomized female rats. *Po0.05 compared to corresponding
sham-operated group; #Po0.05 compared to corresponding male
group.
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Figure 5 | Renal mRNA expression of PPARa and its downstream
genes in 5/6 Nx rats. Kidney samples of male and female rats were
collected 7 weeks after Nx. Renal mRNA expression of PPARa,
AOX, Cyp4a1, and Cyp4a2/3 was quantified with the bDNA signal
amplification assay. Y axis represents renal mRNA of target genes
expressed as RLU per 4 mg total RNA. N¼ 6–7. Error bars indicate
s.e.m. (a) PPARa, (b) AOX, (c) negative correlation of renal PPARa
mRNA with proteinuria in Nx-males and -females, (d) negative
correlation of renal AOX mRNA with proteinuria in Nx-males
and -females; (e) Cyp4a1; (f) Cyp4a2/3; (g) negative correlation of
renal Cyp4a1 mRNA with renal caspase-3 activity in Nx-females; and
(h) positive correlation of renal Cyp4a1 mRNA with blood levels of
hemoglobin in Nx-males. SM, sham-operated male rats; NxM, 5/6
nephrectomized male rats; SF, sham-operated female rats; NxF, 5/6
nephrectomized female rats. *Po0.05 compared to corresponding
sham-operated group; #Po0.05 compared to corresponding
male group.
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whereas males had twofold higher Cyp4a2/3 (Figure 5f).
Renal Cyp4a1 mRNA was further increased by 48% in Nx-
females, but remained unchanged in Nx-males, resulting in a
threefold higher Cyp4a1 expression in Nx-females than Nx-
males (Figure 5e). Renal Cyp4a2/3 tended to decrease in both
genders of Nx rats (Figure 5f). In Nx-females, Cyp4a1
expression correlated negatively with renal caspase-3 activity
(Figure 5g) as well as inflammatory cytokines and death
receptors, including IL-1b (r¼0.76), IL-10 (r¼0.82), Fas
(r¼0.85), and Fas Ligand (r¼0.84). In Nx-males, renal
Cyp4a1 correlated with blood hemoglobin (Figure 5h), and
tended to correlate with CrCl (r¼ 0.72) and caspase-3
activity (r¼0.61).
Gender difference in renal expression of AhR and WT1
The basal renal mRNA expression of AhR was 150% higher in
females than in males (Figure 6a). Renal AhR transcripts
decreased 37% in Nx-females, but remained unchanged in
Nx-males (Figure 6a). Renal AhR transcripts correlated
negatively with urinary excretion of creatinine (r¼0.77)
and GFR (Figure 6b) in Nx-males and Nx-females,
respectively. Moreover, in both genders, renal AhR tended
to correlate negatively with CrCl. Renal WT1 mRNA was
similarly decreased in both genders of Nx rats (Figure 6c).
However, the AhR ligand benzo[a]pyrene disrupts nephro-
genesis by markedly decreasing a 52-kDa WT1 isoform via
increasing the ratio of KTS/þKTS (lysine-threonine-
serine) WT1 mRNA variants, without affecting renal levels
of total WT1 mRNA.15 Thus, we hypothesized that
differential AhR expression in Nx rats results in differential
expression of the 52-kDa WT1 isoform. As shown in Figure
6d, the 62-kDa WT1 protein remained unchanged in both
genders of Nx rats. However, the 52-kDa WT1 isoform
almost completely disappeared in Nx-males, but remained at
high levels in Nx-females.
DISCUSSION
The present studies demonstrate a clear gender difference in
CKD progression in rats. Nx-males have markedly elevated
blood urea nitrogen and decreased CrCl, develop significant
proteinuria, albuminuria, anemia, and malnutrition; in
contrast, Nx-females have only moderate kidney injury, and
are free of albuminuria, anemia, and malnutrition. Nx-males
also have systemic and renal inflammation, which are largely
absent in Nx-females. The present studies provide the first
evidence of gender divergences in renal expression of sex
hormone receptors (Figure 4) and metabolism of steroid
hormones (Figure 3).
Many CKD patients progress to end-stage renal disease
and require kidney transplantation. Chronic rejection of
renal transplants is a major obstacle for long-term success;
the risk of chronic rejection is particularly high when female
kidney is transplanted into a male recipient.25 Both sex
hormones and donor gender affect long-term outcome of
renal transplantation.26,27 Numerous studies have shown that
estrogens are essential for maintaining function of female
kidneys, whereas male kidneys benefit from the absence of
testosterone in rats.24,26–28 For the first time, this study
demonstrates remarkable gender divergences in renal expres-
sion of ERa and AR. The very low blood testosterone in
female Sprague–Dawley rats is consistent with a recent
report.29 Moreover, male kidney is a site of testosterone
catabolism, whereas female kidney is a site of testosterone
production, consistent with human female kidney being an
androgen-producing organ.30 Thus, female kidneys rely on
high estrogen and glucocorticoid as well as low androgen
concentrations in the blood to maintain homeostasis of
steroid hormones. Transplantation of a female kidney to a
male recipient will result in low estrogen and ERa, low
glucocorticoid, but high testosterone and AR, markedly
disrupting renal homeostasis of steroid signaling, leading to
accelerated renal failure.25 Postmenopausal CKD women,
who may have intrinsically lower renal expression of ERa,
suffer from the marked decrease of blood E2 and resultant
accelerated deterioration of renal function.
Among 13 mouse tissues, kidney has the third largest
number of E2-regulated genes.
31 Many studies have shown
that cellular levels of hormone receptors play a key role in
determining local hormonal responses. The current study, for
the first time, demonstrates that in Nx-male rats, renal ERa
transcripts, rather than circulatory estrogens, correlate with
multiple markers of kidney disease. Similarly, renal expres-
sion of ERa, rather than circulatory E2, controls renal
function in female mice genetically prone to glomerulo-
sclerosis.32 Our study is the first report indicating in males,
without any genetic defect, renal ERa expression may be a key
determinant of CKD severity. Moreover, this study provides
the first evidence of renal induction of AR in Nx-males. In
0
1
2
3
W
T1
 m
R
N
A
0
10
20
30
40
50a b
c d
SM NxM SF NxF
SM NxM SF NxF
Ah
R
 m
R
N
A
#
*#
*
*
Sham Nx
Female
Male
62 kDa
52 kDa
62 kDa
52 kDa
r = –0.854
P < 0.02
15
20
25
30
35
40
0.2 0.4 0.6 0.8 1 1.2
GFR (ml/min)
Ah
R
 m
R
N
A
Figure 6 | Renal expression of AhR and WT1 in 5/6 Nx rats. Kidney
samples of male and female rats were collected 7 weeks after Nx.
Renal mRNA expression of AhR and WT1 was quantified with the
bDNA signal amplification assay. Renal protein expression of WT1
was determined by Western blot. Y axis represents renal mRNA of
target genes expressed as RLU per 4 mg total RNA. N¼ 6–7. Error bars
indicate s.e.m. (a) AhR mRNA, (b) negative correlation of renal AhR
mRNA with GFR in Nx-females, (c) WT1 mRNA, and (d) WT1 protein.
SM, sham-operated male rats; NxM, 5/6 nephrectomized male rats;
SF, sham-operated female rats; NxF, 5/6 nephrectomized female rats.
*Po0.05 compared to corresponding sham-operated group; #Po0.05
compared to corresponding male group.
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rats transfected with the renin gene, the AR antagonist
flutamide ameliorated kidney damage.33 Thus, an AR
antagonist may be promising in treating CKD.
Glucocorticoids protect endothelial and epithelial cells
from stress-induced apoptosis, but induce apoptosis of
mature lymphocytes, exhibiting potent anti-inflammatory
effects.34,35 Dexamethasone ameliorated angiotensin II-in-
duced renal damage.36 11b-Hydroxysteroid dehydrogenase-1
is an enzyme that biotransforms inactive cortisone to
bioactive cortisol in proximal tubules. Both GR (Figure 4a)
and 11b-hydroxysteroid dehydrogenase-1 (data not shown)
decrease in Nx rats, with more dramatic decreases observed
in Nx-females. However, only in Nx-males do the decreases
correlate with kidney disease, suggesting that a mechanism
exists in Nx-females to counteract decreases of GR and
11b-hydroxysteroid dehydrogenase-1. Moreover, both blood
levels of E2 (Figure 3b) and renal ERa (Figure 4c) tend to
decrease in Nx-females. Apparently, other mechanisms
besides estrogens and glucocorticoids exist, contributing to
less inflammation and renal injury in Nx-females.
PPARa has a pivotal role in inflammation control.37,38
This study provides the first evidence of a considerable
gender difference in renal expression of PPARa, AOX, and
Cyp4a during CKD. Moreover, renal PPARa and AOX
correlate with multiple markers of CKD in both genders.
AOX is crucial in fatty acid metabolism;39 downregulation
of AOX will not only impair energy supply, but lead to
the accumulation of fatty acyl-CoA, which may cause lipo-
toxicity.
The development of monogenic hypertension in Cyp4a14-
null mice clearly demonstrates the physiological importance
of Cyp4a.40 Moreover, polymorphism of CYP4A11, present
in proximal tubules,41 is associated with human hyper-
tension.42 Interestingly, both rat Cyp4a1 and mouse
Cyp4a1440 are female-predominant in kidneys. The female-
predominant renal expression of Cyp4a1 is further increased
in Nx rats (Figure 5e).
Among the four isoforms of rat Cyp4a, Cyp4a1 has the
highest capacity to metabolize saturated fatty acids (e.g.
lauric acid and palmitic acid) and w/w-1-hydroxylation of
arachidonic acid and epoxyeicosatrienoic acids.43,44 20-
Hydroxyeicosatetraenoic acid is a major w/w-1-hydroxylation
product of arachidonic acid. Depending on the site of
generation, 20-hydroxyeicosatetraenoic acid plays a dual role
in regulating blood pressure via its ability to induce
contraction, as well as to inhibit sodium reabsorption.45,46
Renal expression of Cyp4a1 is predominant in proximal
tubules,7 where both 20-HETE and epoxyeicosatrienoic acids
inhibit sodium reabsorption, increase sodium excretion, and
inhibit the development of hypertension.47 In contrast,
Cyp4a2 and 4a3 are detected in all nephron segments.48
Moreover, renal expression of Cyp4a1, but not Cyp4a2, is
induced by the PPARa ligand clofibrate.49 Interestingly, in
Nx-females, Cyp4a1 expression correlates negatively with
various inflammatory cytokines and apoptosis, suggesting an
important role of Cyp4a1 upregulation in preventing
inflammation and apoptosis in Nx-females. Release of
palmitic acid-derived free fatty acids was shown to be a key
early event in Fas-induced apoptosis.50 Thus, Cyp4a1 may
inhibit apoptosis through decreasing cellular concentrations
of palmitic acid. Moreover, Cyp4a1 catalyzes the formation of
omega-alcohols of epoxyeicosatrienoic acids, high-affinity
PPARa activators.44 Inhibition of nuclear factor-kB activa-
tion through inducing IkBa is a putative mechanism of anti-
inflammation by PPARa ligands.51 Moreover, the PPARa
activator fenofibrate induces renal expression of Cyp2c23, a
major enzyme in producing the anti-inflammatory epoxy-
eicosatrienoic acids.52 Hence, upregulation of Cyp4a1 might
play a key role in activating PPARa and thus preventing the
reduction of AOX (Figure 5b), and meanwhile induce
important anti-inflammatory genes.
Taken collectively, this study strongly suggests a critical
protective role of PPARa and its downstream genes AOX and
Cyp4a1 against CKD progression. Correspondingly, the
PPARa ligand clofibrate is renoprotective in Nx rats.53
Currently, the mechanism of renal induction of Cyp4a1 in
Nx-females remains unknown. Although Cyp4a1 is a well-
characterized PPARa-regulated gene, renal Cyp4a1 expression
is also regulated negatively by androgens.54 Thus, despite a
slight downregulation of PPARa, a putative decrease in renal
androgen (Figure 3d) and AR may contribute to renal
induction of Cyp4a1 in Nx-females.
This study provides the first evidence of gender-divergent
renal expression of AhR in rats. In both Nx males and
females, renal AhR expression correlates positively with CKD
severity, suggesting a pathogenic role of AhR activation in
CKD. The critical role of WT1 in kidney development is
established by the lack of kidney in WT1-null mice, the
abnormality of kidney in WT1 heterozygous mice, and the
existence of WT1 mutation in WT.55,56 Heterozygous mice
with decreased levels of þKTS WT1 variant develop
glomerulosclerosis and are a model for Frasier syndrome.57
Our novel finding of a selective dramatic decrease of the 52-
kDa WT1 protein in Nx-males is remarkably similar to that
in kidneys of mice treated with the AhR ligand benzo[a]pyr-
ene,15 and a marked decrease of renal AhR in Nx-females is
associated with better GFR and preservation of the 52-kDa
WT1 protein. Therefore, in Nx-females, a marked decrease of
renal AhR might cause an increase of þKTS variants,
preventing the decrease of the 52-kDa WT1 protein and CKD
pathogenesis. In fact, resveratrol, a natural AhR antagonist,
inhibited proteinuria, hypoalbuminemia, and hyperlipidemia
in nephritic rats.58
Conclusion
This study identifies key molecular pathways contributing to
the marked gender difference in CKD progression: ERa, AR,
PPARa/AOX/Cyp4a1, AhR, and WT1. These pathways are
relatively independent; however, apparent interactions be-
tween these pathways exist. The beneficial alterations of these
pathways in Nx-females may function in concert to protect
female kidneys during CKD. Future combination therapy
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simultaneously targeting these pathways, mimicking bene-
ficial adaptive responses in female Nx rats, may achieve a
much better efficacy than the current modalities in treating
CKD.
MATERIALS AND METHODS
Materials
Bradford reagent and diagnostic kits for creatinine and urea
nitrogen were purchased from Sigma Inc. (St Louis, MO, USA).
Diagnostic kits for albumin and glucose were obtained from Stanbio
Laboratory (Boerne, TX, USA). Radioimmunoassay kits for
corticosterone, E2, and testosterone were purchased from ICN
Pharmaceuticals Inc. (Orangeburg, NY, USA).
Animals
The 5/6 Nx and sham-operated adult male and female Sprague–-
Dawley rats were purchased from Charles River Laboratories Inc.
(Wilmington, MA, USA). Rats (175–225 g) were randomly allotted
to 5/6 nephrectomy or sham-operated groups. Five-sixth nephrect-
omy of seven male and seven female rats was performed by surgical
resection of the 2/3 of the right kidney, followed by removal of the
left kidney 1 week later. Six males and seven females underwent
sham operation as controls. Following nephrectomy or sham
operation, rats were allowed 1 week to recover and then transferred
to an American Animal Associations Laboratory Animal Care-
accredited facility at our institution. Rats were housed in an ambient
temperature of 221C with alternating 12-h light/dark cycles,
and allowed water and rat chow ad libitum (Teklad; Harlan,
Table 2 | Oligonucleotide probes for the analysis of rat mRNA by bDNA signal amplification assay
Targeta Functionb Targeta Functionb Targeta Functionb Targeta Functionb Targeta Functionb
ERa GR PPARa Cyp4a1 AOX
418–434 CE 1546–1566 CE 743–760 CE 362–379 CE 3247–3272 CE
493–513 CE 1591–1614 CE 806–827 CE 551–569 CE 3446–3471 CE
514–532 CE 1704–1725 CE 908–932 CE 668–693 CE 3522–3546 CE
620–639 CE 1886–1908 CE 956–978 CE 873–895 CE 3613–3634 CE
640–665 CE 1523–1545 LE 1066–1088 CE 312–337 LE 3273–3298 LE
396–417 LE 1615–1636 LE 761–781 LE 338–361 LE 3299–3318 LE
435–451 LE 1752–1771 LE 782–805 LE 380–399 LE 3365–3386 LE
472–492 LE 1772–1792 LE 828–848 LE 400–419 LE 3387–3405 LE
533–554 LE 1793–1818 LE 868–887 LE 420–442 LE 3406–3424 LE
577–598 LE 1819–1839 LE 888–907 LE 505–527 LE 3425–3445 LE
599–619 LE 1867–1885 LE 933–955 LE 528–550 LE 3472–3499 LE
666–690 LE 1567–1590 BL 979–999 LE 597–623 LE 3500–3521 LE
691–712 LE 1637–1657 BL 1047–1065 LE 646–667 LE 3547–3571 LE
452–471 BL 1658–1677 BL 1089–1112 LE 694–714 LE 3572–3593 LE
555–576 BL 1678–1703 BL 1113–1133 LE 786–806 LE 3594–3612 LE
1726–1751 BL 849–867 BL 830–853 LE 3635–3659 LE
AR 1840–1866 BL 1000–1021 BL 854–872 LE 3660–3683 LE
629–647 CE 1022–1046 BL 443–462 BL 3319–3342 BL
648–670 CE AhR 463–480 BL 3343–3364 BL
760–779 CE 2373–2389 CE WT1 481–504 BL
851–870 CE 2410–2431 CE 463–480 CE 570–596 BL FasL
910–933 CE 2451–2472 CE 481–497 CE 624–645 BL 785–804 CE
954–974 CE 2535–2552 CE 554–569 CE 715–735 BL 968–994 CE
671–694 LE 2614–2636 CE 632–648 CE 736–761 BL 1017–1038 CE
718–737 LE 2309–2330 LE 570–589 LE 762–785 BL 1173–1194 CE
780–797 LE 2331–2351 LE 590–610 LE 807–829 BL 1219–1240 CE
798–816 LE 2352–2372 LE 611–631 LE 805–830 LE
832–850 LE 2432–2450 LE 649–668 LE Fas 832–861 LE
871–887 LE 2473–2494 LE 669–692 LE 832–853 CE 862–887 LE
934–953 LE 2495–2513 LE 693–713 LE 895–917 CE 888–913 LE
975–996 LE 2575–2593 LE 498–514 BL 937–957 CE 915–943 LE
695–717 BL 2594–2613 LE 515–537 BL 980–1004 CE 944–967 LE
738–759 BL 2390–2409 BL 538–553 BL 1051–1072 CE 1063–1084 LE
817–831 BL 2514–2534 BL 854–876 LE 1107–1129 LE
888–909 BL 2553–2574 BL 877–894 LE 1130–1149 LE
918–936 LE 1195–1218 LE
959–979 LE 995–1016 BL
1005–1028 LE 1039–1062 BL
1073–1091 LE 1085–1106 BL
1092–1112 LE
1029–1050 BL
AOX=acyl-CoA oxidase; AhR=aryl hydrocarbon receptor; AR=androgen receptor; bDNA=branched DNA; Cyp4a1=cytochrome P450 4a1; ERa=estrogen receptor a; FasL=Fas
ligand; GR=glucocorticoid receptor; PPARa=peroxisome proliferator-activated receptor a; WT1=Wilm’s tumor 1.
aTarget refers to the sequence of the mRNA transcript as enumerated in the GenBank file. Genebank ID: ERa, 6978814; AR, 6978534; GR, 204271; AhR, 6978474; PPARa,
6981381; AOX, 8394148; Cyp4a1, 28460697; WT1, 13928719; Fas, 59624976; FasL, 6978524.
bFunction refers to the use of the oligonucleotide probe in the bDNA assay (CE, capture extender; LE, label extender; BL, blocker probe). An oligonucleotide of
TTTTTctcttggaaagaaagt is linked to the 30-end of each CE. An oligonucleotide of TTTTTaggcataggacccgtgtct is linked to the 30-end of each LE.
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Indianapolis, IN, USA). Seven weeks after 5/6 nephrectomy or sham
operation, each rat was individually housed in a metabolic cage and
given food and water ad libitum for 24 h. Urine of each rat was
collected, quantified, and then stored at 801C. After pentobarbital
anesthesia, rat blood samples were drawn by cardiac puncture into
glass tubes containing ethylenediaminetetraacetic acid. Rat blood
sample (1 ml) was analyzed for complete blood count by Physicians
Reference Laboratory (Overland Park, KS, USA). The remaining
blood samples were centrifuged and the plasma was aliquoted and
stored at 801C. The remnant kidney and spleen were collected,
weighed, and snap-frozen in liquid nitrogen for storage at 801C.
Blood and urine levels of creatinine, urea nitrogen, and albumin
were analyzed with diagnostic kits following the manufacturers’
instructions. The formula to calculate CrCl was as follows: urine
creatinine (mg/dl) urine volume (ml)/blood creatinine (mg/dl)/
time (min). The formula for the calculation of GFR was:
GFR¼ (urea clearanceþCrCl)/2.
RNA extraction
Total tissue RNA was extracted using RNA-Bee reagent (Tel-Test
Inc., Friendswood, TX, USA) according to the manufacturer’s
protocol. RNA pellets were redissolved in diethyl pyrocarbonate-
treated water and quantified by ultraviolet absorbance at 260 nm.
RNA integrity was confirmed by agarose gel electrophoresis of 5 mg
of total RNA and visualization of the intact 18S and 28S bands by
ethidium bromide staining.
bDNA signal amplification assay
The mRNA of genes examined was quantified using the bDNA assay
(Quantigene bDNA signal amplification kit; Genospectra, Fremont,
CA, USA) with modifications.59 Sequences of target genes were
accessed from GenBank (www.ncbi.nlm.nih.gov/Genbank). The
probes of rat Cyp4a2/3,60 IL-1b, IL-6, and IL-1061 have been
reported previously. The names and Genebank accession number for
probes of other rat genes are given in Table 2. All reagents for
analysis were supplied in the Quantigene bDNA signal amplification
kit. Total RNA (4 mg/well) was added to each well of a 96-well plate.
Subsequent incubation, washing, and hybridization steps were
carried out following the manufacturer’s protocol. Luminescence
of the 96-well plate was determined with a Quantiplex 320 bDNA
luminometer interfaced with Quantiplex Data Management soft-
ware version 5.02 for data analysis. The luminescence for each well is
reported as relative light units (RLU) per 4 mg of total RNA.
Determination of caspase-3 activity in kidney
Renal caspase-3 activity was quantified as an indicator of apoptosis.
Kidney samples were homogenized in cell lysis buffer (5% (wt/vol))
provided in the caspase-3 kit (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA). Protein levels of kidney homogenates were
determined with Bradford reagent. A 20 ml aliquot of 5% kidney
homogenates was used to determine caspase-3 activity following the
manufacturer’s instructions. The fluorescent product was detected at
505 nm upon excitation at 400 nm by an LS50B luminescence
spectrometer (Perkin-Elmer Inc., Boston, MA, USA). Caspase-3
activity was expressed as RLU per mg protein.
Western blot analysis of renal protein expression of ERa and
WT1
Kidney tissues were homogenized in a buffer (25 mM 2-[4-(2-
hydroxyethyl)-1-piperazinyl]ethanesulfonic acid, pH 7.6, 1.5 mM
ethylenediaminetetraacetic acid, 10% glycerol, 1 mM dithiothreitol,
0.1 mg/ml phenylmethylsulfonyl fluoride, 0.5 M KCl, and 1
protease inhibitor cocktail). After being incubated on ice for 1 h,
the homogenates were centrifuged at 100 000 g for 30 min at 41C.
The resultant supernatant was stored at 801C. Protein concentra-
tions were determined with Bradford reagent. Protein expression of
ERa and WT1 was determined by Western blot.62 Briefly, protein
samples were boiled for 2 min and loaded to 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis gels. After electrophoresis,
proteins were transferred to polyvinylidine difluoride membranes
and filters probed with an ERa (sc-542) or WT1 (sc-846) polyclonal
antibody (Santa Cruz Biotechnologies Inc). Signals were visualized
with horseradish peroxidase-conjugated secondary antibody.
Statistics
Data are presented as mean7s.e. of 6–7 kidney tissues. Differences
between groups were determined by analysis of variance, followed by
Duncan’s multiple-range test with significance set at Po0.05.
Correlation analysis was conducted with Correlation Matrices
within Statistica for Windows release 4.5 (StatSoft Inc., Tulsa, OK,
USA).
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